Causes, epidemiology, and treatment of bronchial infections

Infections in Medicine

Volumn 17, Issue 3, 2000, Pages 186-198

  Ball, Peter ^a   Chodosh, Sanford ^b   Grossman, Ronald ^c   Tillotson, Glenn ^d   Wilson, Robert ^e  

^a UNIVERSITY OF ST ANDREWS   (United Kingdom)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

^d BAYER CORPORATION   (United States)

^e ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

Acute exacerbation of chronic bronchitis (AECB); Antimicrobial resistance; Antimicrobial therapy, empiric; Chronic bronchitis; Chronic obstructive pulmonary disease (COPD)

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZITHROMYCIN; CEFACLOR; CEFEPIME; CEFIXIME; CEFPROZIL; CEFUROXIME AXETIL; CIPROFLOXACIN; CLARITHROMYCIN; COTRIMOXAZOLE; DOXYCYCLINE; LEVOFLOXACIN; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; TETRACYCLINE; TETRACYCLINE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE SEVERITY; DRUG EFFICACY; HAEMOPHILUS INFLUENZAE; HUMAN; INCIDENCE; LUNG INFECTION; MORTALITY; REVIEW; TREATMENT PLANNING; UNITED STATES;

EID: 0034020826     PISSN: 07496524     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. Higgins MW, Thorn T. Incidence, prevalence and mortality: intra-and intercountry differences. In Hensley MJ, Saunders NA, eds. Clinical Epidemiology of Chronic Obstructive Pulmonary Disease. New York Marcel Dekker; 1990:23-43.
2. Higgins M. Epidemiology of pulmonary disease. In Casaburi R, Petty TI, eds. Principles and Practice of Pulmonary Rehabilitalion. Philadelphia: WB Saunders Co; 1993:10-17.
3. National Center for Health Statistics. Advance Report of Final Mortality Statistics, 1994; Mon Vital Stat Rep. 1996:45(suppl):23.
4. American Thoracic Society. Standards for diagnosis and care of patients with chronic obstructive pulmonary disease. Definitions, epidemiology, pathophysiology, diagnosis, and staging. Am J Respir Crit Care Med. 1995;152(suppl):S78-S120.
5. Morbidity and Mortality: 1996 Chartbook on Cardiovascular, Lung and Blood Diseases. Bethesda, Md: National Heart, Lung, and Blood Institute, National Institutes of Health; May 1996:52
6. Frank SH, Jaen CR. Office evaluation and treatment of the dependent smoker. Prim Care. 1993;20:251-268.
7. Morbidity and Mortality: 1996 Chartbook on Cardiovascular, Lung and Blood Diseases. Bethesda, Md: National Heart, Lung, and Blood Institute, National Institutes of Health; May 1996:14.
8. Wynder EL, Fairchild EP Jr. The role of a history of persistent cough in the epidemiology of lung cancer. Am Rev Respir Dis. 1996;94:709-720.
9. Sherrill DL, Lebowitz MD, Burrows B. Epidemiology of chronic obstructive pulmonary disease. Clin Chest Med. 1990;11:375-387.
10. Morano MA. Current Estimates From the National Health Interview Survey, 1994. Washington, DC: National Center for Health Statistics; 1996. DHHS publication PHS96-1521 (Vital and Health Statistics, series 10, No. 193).
11. National Center for Health Statistics. National Health Interview Survey. Vital Health Stat 13. (issues from 1974 to 1995).
12. Wilder C. Prevalence of Selected Chronic Respiratory Conditions: United States, 1970. Washington, DC: National Center for Health Statistics. Data for the National Health Survey. 1973;10:15-17.
13. Balgos AA. Guidelines for the role of antibiotics in acute exacerbations of chronic bronchitis in the Asia-Pacific region: report and recommendations of a consensus group. Med Progress. 1998;25(11):29-38.
14. Jardim JR and Latin American Consensus Group. Consenso Latinoamericano sobre infecciones en bronquitis cronica. Revista Panamericana de Infectologia. 1997;1:3-19.
15. Higgins M. Risk factors associated with chronic obstructive lung disease. Ann N Y Acad Sci. 1991;624:7-17.
16. Petty TL, Silvers W, Stanford RE. Mild emphysema is associated with reduced elastic recoil and increased lung size, but not with airflow limitation. Am Rev Respir Dis. 1987;136:867-876.
17. ICD-9-CM Coding Handbook. Willowbrook, Ill: Professional Medical Management Corp; 1989.
18. Monso E, Ruiz J, Rosell A, et al. Bacterial infection in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1995;152:1316-1320.
19. Gump DW, Phillips CA, Forsyth BR, et al. Role of infection in chronic bronchitis. Am Rev Respir Dis. 1996;113:465-474.
20. Beaty CD, Grayston TJ, Wang SP, et al: Chlamydia pneumonia, strain TWAR, infection in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis. 1991;144:1408-1410.
21. Smith CB, Golden CE, Kanner RE, et al. Association of viral and Mycoplasma pneumoniae infections with acute respiratory illness in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis. 1980;121:225-232.
22. Saetta M, Di Stefano A, Maestrelli P, et al. Airway eosinophilia in chronic bronchitis during exacerbations. Am J Respir Crit Care Med. 1994; 150:1646-1652.
23. Murphy TF, Sethi S. Bacterial infection in chronic obstructive pulmonary disease. Am Rev Respir Dis. 1992;146:1067-1083.
24. Basran GS, Joseph J, Abbas AMA, et al. Treatment of acute exacerbations of chronic obstructive airways disease: a comparison of amoxycillin and ciprofloxacin. J Antimicrob Chemother. 1990;26(suppl F):19-24.
25. Chodosh S. Bronchitis and asthma. In: Gorbach SL, Bartlett JG, Blacklow NR, eds. Infections Diseases. Philadelphia: WB Saunders Co; 1992:476-485.
26. Ball P. Efficacy and safety of cefprozil versus other beta-lactam antibiotics in the treatment of lower respiratory tract infections. Eur J Clin Microbiol Infect Dis. 1994;13:851-856.
27. Ball P. Epidemiology and treatment of chronic bronchitis and its exacerbations. Chest. 1995; 108:43S-52S.
28. Leeper K, Jones AM, Tillotson G. The changing etiology of chronic obstructive pulmonary disease (COPD). In: Program and abstracts of the 63rd Annual Congress of the American College of Chest Physicians; October 27-30, 1997; New Orleans. Abstract 215.
29. Hill SL, Pye A, Johnson MM, et al. A role for Haemophilus parainfluenzae in chronic lung disease. Am J Respir Crit Care Med. 1997;155:105.
30. Thornsberry C, Ogilvie P, Kahn J, et al. Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season. The Laboratory Investigator Group. Diagn Microbiol Infect Dis. 1997;29: 249-257.
31. Doern GV, Brueggemann AB, Pierce G, et al. Prevalence of antimicrobial resistance among 723 outpatient clinical isolates of Moraxella catarrhalis in the United States in 1994 and 1995: results of a 30-center national surveillance study. Antimicrob Agents Chemother. 1996;40: 2884-2885.
32. Doern GV, Brueggemann AB, Holley HP Jr, et al. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study. Antimicrob Agents Chemother. 1996; 40:1208-1213.
33. Clairoux N, Picard M, Brochu A, et al. Molecular basis of non-beta-lactamase-mediated resistance to beta-lactam antibiotics in strains of Haemophilus influenzae isolated in Canada. Antimicrob Agents Chemother. 1992;36:1504-1513.
34. Balter MS. Recommendations on the management of chronic bronchitis. A practical guide for Canadian physicians. Can Med Assoc J. 1994; 151(suppl 10):5-23.
35. Doern GV, Jorgensen JH, Thornsberry C, et al. Prevalence of antimicrobial resistance among clinical isolates of Haemophilus influenzae: a collaborative study. Diagn Microbiol Infect Dis. 1986;4:95-107.
36. Doern GV, Jorgensen JH, Thornsberry C, et al. National collaborative study of the prevalence of antimicrobial resistance among clinical isolates of Haemophilus influenzae. Antimicrob Agents Chemother. 1988;32:180-185.
37. Grüneberg RN, Felmingham D, and the Alexander Project Group. Results of the Alexander Project: a continuing, multicenter study of the antimicrobial susceptibility of community-acquired lower respiratory tract bacterial pathogens. Diagn Microbiol Infect Dis. 1996;25:161-181.
38. Doern GV, Pfaller MA, Kugler K, et al. Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY antimicrobial surveillance program. Clin Infect Dis. 1998;27:764-770.
39. Spika JF, Facklam RR, Plikaytis BD, et al. Antimicrobial resistance of Streptococcus pneumoniae in the United States, 1979-1987. J Infect Dis. 1991;163:1273-1278.
40. Jorgensen JH, Doern GV, Maher LA, et al. Antimicrobial resistance among respiratory isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae in the United States. Antimicrob Agents Chemother. 1990;34:2075-2080.
41. Thornsberry C, Burton PH, Vanderhoof BH. Activity of penicillin and three third-generation cephalosporins against US isolates of Streptococcus pneumoniae: a 1995 surveillance study. Diagn Microbiol Infect Dis. 1996;25:89-95.
42. Mathies AW Jr. Penicillins in the treatment of bacterial meningitis. J R Coll Physicians Lond. 1972;6:139-146.
43. Felmingham D, Grüneberg RN, and the Alexander Project Group. A multicenter collaborative study of the antimicrobial susceptibility of community-acquired, lower respiratory tract pathogens, 1992-1993: The Alexander Project. J Antimicrob Chemother. 1996;38(suppl A): 1-57.
44. Chen DK, McGeer DK, Azavedo JC, et al. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N Engl J Med. 1999;341:233-239.
45. Plouffe JF, Breiman RF, Facklam RR, for the Franklin Country Pneumonia Study. Bacteremia with Streptococcus pneumoniae: implications for therapy and prevention. JAMA. 1996; 275:194-198.
46. Anthonisen NR, Manfreda J, Warren CPW, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987;106:196-204.
47. Allegra L, Grassi C, Grossi A, et al. Guolo degli antibiotici nel tratamento delle riacutizza della broncite cronica. Ital J Chest Dis. 1991;45: 38-48.
48. Ball P, Harris JM, Lowson D, et al. Acute infective exacerbations of chronic bronchitis. QJM. 1995;88:61-68.
49. Niederman MS. Acute exacerbations of chronic bronchitis: the role of infection and the selection of appropriate therapy. Pulm Crit Care Update. 1996;11:1-7.
50. Eller J, Ede A, Schaberg T, et al. Infective exacerbations: chronic bronchitis, relation between bacteriologic etiology and lung function. Chest. 1998;113:1542-1548.
51. Chodosh S, Schreurs A, Siami G, et al. Efficacy of oral ciprofloxacin vs clarithromycin for treatment of acute bacterial exacerbations of chronic bronchitis. Clin Infect Dis. 1998;27:730-738.
52. Anzueto A, Rizzo JA, Grossman RF. The infection-free interval: its use in evaluating antimicrobial treatment of acute exacerbation of chronic bronchitis. Clin Infect Dis. 1999;28:1344-1345.
53. Wilson APR, Grüneberg RN, eds. Ciprofloxacin: 10 Years of Clinical Experience. Oxford, England: Maxim Medical; 1997:13-37.
54. Lee BL, Kimbrough RC, Jones SR, et al. Infectious complications with respiratory pathogens despite ciprofloxacin therapy. N Engl J Med. 1991;325:520-521.
55. Wilson APR, Grüneberg RN, eds. Ciprofloxacin: 10 Years of Clinical Experience. Oxford, England: Maxim Medical; 1997:115-125.
56. Grossman R, Mukherjee J, Vaughan D, et al. A 1 year community-based health economic study of ciprofloxacin vs. usual antibiotic treatment in acute exacerbations of chronic bronchitis. Chest. 1998;113:131-141.
57. Sethi S, Klingman KL, Evans N, et al. Exacerbations of COPD are associated with acquisition of new strains of bacterial pathogens. In: Program and abstracts of the 34th Annual Meeting of the American Thoracic Society; May 18-21, 1996; New Orleans. Abstract A825.
58. Chodosh S. Treatment of acute exacerbations of chronic bronchitis: state of the art. Am J Med. 1991;91(suppl 6A):87S-92S.
59. Wilson R, Tillotson G, Ball P. Clinical studies in chronic bronchitis: a need for better definition and classification of severity. J Antimicrob Chemother. 1996;37:205-208.
60. Wilson R, Wilson CB. Defining subsets of patients with chronic bronchitis. Chest. 1997; 112(suppl):303S-309S.
61. Destache CJ, Dewan N, O'Donahue WJ, et al. Clinical and economic considerations in the treatment of acute exacerbations of chronic bronchitis. J Antimicrob Chemother. 1999;43 (suppl A):107-113.
62. Chodosh S. Quinolones in acute bacterial exacerbations of chronic bronchitis. In: Siporin C, Heifetz J, Dumagala J, et al, eds: The New Generation of Quinolones. New York: Marcel Dekker; 1990:249-297.
63. American Thoracic Society. Guidelines for the initial management of adults with community acquired pneumonia: diagnosis, assessment of severity and initial antimicrobial therapy. Am Rev Respir Dis. 1993;148:1418-1426.
64. Ball P, Fernald A, Tillotson G. Therapeutic advances of new fluoroquinolones. Exper Opin Invest Drugs. 1998;7:1-23.
65. Wilson R, Kubin R, Ballin I, et al. Five day moxifloxacin therapy compared to seven day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis. J Antimicrob Chemother. 1999;44:501-503.